Haploidentical hematopoietic stem cell transplantation as promising therapy in the improved survival of pediatric patients with leukemias and myelodysplasias

Table 3 Conditioning, event-free survival and overall survival of the analyzed patients

Ref.	Haplo transplant cohort, n	Conditioning regimens (all cohorts)				Haplo cohort
		I	II	III	IV	EFS (%)	OS (%)
Kim et al[15], 2021	14	MAC: Bu-Flu	MAC: Bu-Flu-TBI	RIC: Bu-Flu-TBI	-	NRS	NRS
Hong et al[16], 2022	35	MAC, Bu, Flu	MAC, Bu, Flu, and Cy	TBI after blinatumomab	-	74.4% (3 years)	88.6% (3 years)
Bertaina et al[17], 2018	98	MAC: Bu	MAC/TBI: TBI-based	Treosulfan based	-	62.0% (5 years)	68.0% (5 years)
Bai et al[18], 2020	181, 087	MAC/chemo: Cytarabine, Cy, Bu, and semustine	-	-	-	89.5% (4 years), NRS	87.4% (4 years); 57.1% (4 years)
Ruggeri et al[19], 2021	180	MAC/chemo	MAC/TBI	RIC	-	38.5%2 (2 years); 65%3; 44%4, and 18.8%5	50.8% (2 years); 76.5%7; 61.2%7; (NRS)
Sun et al[20], 2015	111	MAC: Bu, cycytarabine, and Me-CCNU	MAC/TBI Cy, cytarabine	-	-	79.2% (5 years)	NR
R	19	MAC: Bu, Flu, and melphalan, TBI-based	MAC: Bu-based	RIC	-	42.1% (3 years)	57.4% (3 years)
Paina et al[22], 2018	106	MAC: Bu, Cy, and Lomustin	MAC, Bu-flu	MAC: Treosulfan	RIC: Melphalan; RIC: Bu	NR	33.3% (10 years); 64.7%; 18.1%, (10 years)6
Mo et al[23], 2016	65	Cytarabine, Bu, Cy, and semustine	TBI	MAC: Bu-Flu Carmustine	MAC: CyFlu-TBI	71% (2 years)	82.0% (2 years)
Wang et al[24], 2020	166	RIC: Cy, MTX, MMF	-	-	-	60.2% (100 d)	60.8% (100 d)
Zhang et al[25], 2022	23	MAC: Bu-Cy, hydroxyurea cytarabine, and methy	-	-	-	80.1% (5 years)	81.0% (5 years)
Zheng et al[26], 2020	69	Bu-Cy, cytarabine, semustine	Bu-Cy-Hu, cytarabine, semustine	-	-	72.9% (3 years)	73.0% (3 years)
Trujillo et al[27], 2021	42	RIC: Bu-Flu-TBI	RIC: Flu-Mel-TBI	-	-	46% (3 years)	56% (3 years)
Yang et al[28], 2022	17	Cytarabine, Bu, and Cy Me-CCNU	Cytarabine, Bu-Cy	-	-	NRS	NRS
Bai et al[29], 2022	37	Cytarabine, Bu-Cy, and semustine	-	-	-	65.6% (3 years)	73.0% (3 years)
Miyamura et al[30], 2019	10	MAC, Bu-TBI	RIC, NR	-	-	NRS	NRS
Oevermann et al[32], 2014	85	TBI	Non TBI	-	-	50.6%7 (5 years); 29.5%7 (5 years)	NR
Pérez-Martínez et al[33]	192	Flu-Thiotepa-Mel or Bu	TLI or TBI	-	-	49.2% (2 years)	55.1% (2 years)

¹In the study, 18 patients in the complete remission 1 (CR1) e 8 other patients from the other cohort experiencing relapse opted for allogeneic hematopoietic stem cell transplantation (HSCT, CR2, n = 13, but just 8 patients opted for allogeneic HSCT).

²General.

³CR1.

⁴CR2.

⁵CR3.

⁶CR1 and CR2; patients transplanted beyond the remission.

⁷KIR B haplotype; KIR A haplotype.

NRS: Not reported separately; NR: Not reported; TLI: Traumatic lung injury; TBI: Total body irradiation; MAC: Myeloablative conditioning regimen; RIC: Reduced intensity regimen.